Identity crisis in pulmonary arterial hypertension

G. Ruffenach¹, S. Bonnet¹, S. Rousseaux², S. Khochbin², S. Provencher¹ and F. Perros¹,³
¹Groupe de recherche en hypertension pulmonaire et biologie vasculaire, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, QC, Canada; ²CNRS UMR5309, Inserm U1209, Université de Grenoble Alpes, Institut Albert Bonnioni, Grenoble, France; ³INSERM UMR S 999, Université Paris–Sud, Laboratoire d'Excellence (LabEx) en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France

Abstract
Pulmonary arterial hypertension (PAH) shares many hallmarks with cancer. Cancer cells acquire their hallmarks by a pathological Darwinian evolution process built on the so-called cancer cell “identity crisis.” Here we demonstrate that PAH shares the most striking features of the cancer identity crisis: the ectopic expression of normally silent tissue-specific genes.

Keywords
pulmonary hypertension, cancer hallmarks, tissues-specific gene, Darwinian evolution

Date received: 17 January 2017; accepted: 14 September 2017
Pulmonary Circulation 2017; 8(3) 1–5
DOI: 10.1177/2045893217746054

Introduction
Pulmonary arterial hypertension (PAH) is a pulmonary vascular disease characterized by increased mean pulmonary arterial pressure (mPAP; >25 mmHg). This detrimental rise in pulmonary blood pressure is due to distal pulmonary artery occlusion driven by unregulated proliferation of pulmonary arterial smooth muscle cells (PASMC) and endothelial cells (PAEC) within the foci of complex vascular lesions. During the last decade, landmark studies demonstrated significant parallels between PASMC/EC in cancer and PAH,¹,² which elucidated key mechanisms of PAH pathogenesis.¹,³ Studies describing the acquisition of cancer hallmarks by these vascular cells gave rise to the cancer paradigm of PAH.²

These hallmarks include an increased proliferation rate, evasion of growth suppressor, resistance to apoptosis, cellular energetic deregulation, angiogenesis in foci of complex vascular lesions, sustained inflammation, genetic mutations, and epigenetic modifications.¹,² Similar to what is observed in cancer, epigenetic modifications have been shown to predispose and participate in PAH pathogenesis.⁴,⁵ Indeed, germline mutations in the bone morphogenetic protein receptor II (BMPRII)⁴ and potassium channel subfamily K member 3 (KCNK3)⁶ genes have been demonstrated to participate in PAH development. Furthermore, somatic mutations, single nucleotide polymorphisms, microsatellite instability, and aneuploidy have also recently been found to increase predisposition to PAH.⁵,⁷,⁸ For example, two sisters with heritable PAH carry the same missense mutation in Krüppel-like factor 2 (KLF2), a gene known to participate in nitric oxide vascular homeostasis.⁹ In another PAH patient carrying a BMPRII mutation, Aldred et al.⁷ identified a deletion in chromosome 13 resulting in the deletion of mothers against decapentaplegic homolog 8 (Smad-8). In both cases, these somatic mutations could participate in cancer and PAH pathogenesis. In addition, increased DNA damage followed by increased somatic mutation acquisition has recently been demonstrated in PAH.¹⁰,¹¹ Finally, there is growing evidence for genome-wide epigenetic modifications in PAH that lead to chromatin remodeling and gene expression alterations. These modifications include varied expression of epigenetic modifiers and readers including histone deacetylases (HDACs)¹² and BRD4,¹³ DNA methylation modifications,¹⁴,¹⁵ and microRNAs.¹⁶

Corresponding author:
Frédéric Perros, Inserm UMR S 999 - LabEx LERMIT IPSIT, Université Paris–Sud, Centre Chirurgical Marie Lannelongue, 133 Avenue de la Résistance, Le Plessis-Robinson 92350, France.
Email: frederic.perros@gmail.com

Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
In cancer, genetic mutations and epigenetic modifications pave the way for the so-called cancer cell “identity crisis,” characterized by abnormal repression of cell-type-specific genes (from the differentiated phenotype) concomitant with the aberrant activation of “off-context” genes (normally expressed in other cell types or during different developmental stage) (Fig. 1a). These modifications in gene expression lead to a loss of the cells’ identity (i.e. phenotype) and the development of a full identity crisis (aberrant cell commitment). In cancer, the most striking example of this identity crisis is the activation of normally silent tissue-specific genes, such as male germline or placenta-specific genes. One hypothesis is that the development of this identity crisis provides a fertile ground for initiating a pathological Darwinian evolution process, leading to the acquisition of cancer hallmarks (Fig. 1a). In this view, after the first pro-cancerous event such as genetic and/or epigenetic modification, most altered cells would die from lethal genomic abnormalities. A few of them, however, would survive after accumulating specific “advantageous” genetic and epigenetic modifications leading to clonal expansion and growth. In cancer, this mechanism is supported by the monoclonal nature of cancer cells; whereas in idiopathic PAH (IPAH), clonal PAEC growth may take place within the plexiform lesions. Since PAH shares numerous hallmarks with cancer, we hypothesized that PAH could be characterized by a similar identity crisis and activation of normally silent tissue-specific genes. In order to investigate our hypothesis in the most elegant and irrefutable way, we aimed to identify aberrant activation of normally silent genes by employing a microarray analysis-based strategy that we recently developed.

Methods

Patient population

In this study, we analyzed the lungs of one male and one female with IPAH and one female with PAH associated with systemic scleroderma (mean age = 47 years, mPAP = 49.5 mmHg) and compared them to three non-PAH female lungs (mean age = 64 years). Individuals previously gave signed informed consent in accordance with Laval University and the IUCPQ Biosafety and Ethics Committee (CER20773).

Microarray analysis

The detection of genes ectopically expressed from the transcriptomic analysis was carried out with a similar strategy as described by Rousseau et al. Briefly, using publicly available transcriptomic data from normal human tissue, a list of 506 genes with an expression restricted to the germline or the placenta tissue was defined. An extended list of genes was obtained by adding genes with a predominant expression in the germline, embryonic stem (ES) cells, or in the placenta on the basis of their mean expression level in one of these tissues being above a threshold defined as the mean expression in a series of 112 adult non-germline tissues + 3*standard deviations. The aberrant expressions of the abovementioned genes were systematically detected using the transcriptomic data of the samples from patients with PAH and a threshold value corresponding to the mean value in the three control samples + 3*standard deviations.

Meta-analysis

In order to confirm the expression of genes found to be ectopically expressed in our microarray analysis, we investigated their expression by meta-analysis using the public Illumina microarray repository database, Nextbio. Nextbio allows user-friendly access to microarray data using a consistent analysis pipeline between datasets as described by Kupershmidt et al. We found three relevant microarray datasets in this microarray repository database; namely, GSE53408 comparing the lung gene expression of 11 controls to 12 patients with severe PAH, GSE21284 comparing primary cultured PASMC from two control to two PAH patients, and GSE15197 comparing the lung gene expression of 13 control to 18 PAH patients and eight patients with pulmonary hypertension associated with pulmonary fibrosis.

Results

Our analysis revealed an aberrant expression of 40 genes in all three human PAH lungs (Fig. 1b). Among them, four genes (C15orf32, PSG11, C15orf43, and KRTAP21-1) have normal expression strictly restricted to testis or placenta (Fig. 1b, Group 1), another four (CECR2, TTLL4, MRPS25, QSER1) have predominant expression in ES cells (Fig. 1b, Group 3), and the remaining 32 genes have predominant expression in germline cells (Fig. 1b, Group 2). Furthermore, considering only the genes whose expression is normally restricted to male germline or placenta, we observed the ectopic activation of 47 of these genes in at least one PAH patient (Fig. 1c).

These results were further confirmed by meta-analysis using Nextbio. Indeed, bio-informatics research in the Nextbio database revealed that, despite using a different microarray platform (Illumina vs. Affymetrix array), different approaches and different populations, three previous microarray studies also documented that 18 of the genes identified above have aberrant expression in PAH (Fig. 1d and 1e). Among these 18 genes, 13 of them were found to have altered expression in all three PAH patients (Fig. 1d) and five genes among the 40 genes with restricted tissues-specific expression (Fig. 1e). Presently, most of the genes we identified have no known function, highlighting the probable absence of a functional role in PAH pathogenesis.
Fig. 1. (a) Proposed model of identity crisis leading to PAH pathogenesis by a Darwinian evolution process. Genetic mutation and epigenetic rearrangement lead to aberrant gene expression and identity crisis development. In turn, identity crisis by a Darwinian evolution process gives rise to cancer cells hallmark acquisition and tumor development. In PAH, the same evolutionary process, with different selective pressure, would lead to PAH cancer hallmark acquisition, pulmonary arteries obstruction, and complex intimal lesions. (b) Ectopic expression of highly specific germline, placental, and embryonic genes in PAH lung. Ectopic expression heat map showing the ectopic expression in all human PAH lungs of highly specific germline, placental, and embryonic stem cell genes and their lack of expression in control lungs. Heat map has been divided into three groups: (1) placental and testis restricted expression; (2) germline cells predominant expression; (3) embryonic stem cells predominant expression (c) neo-expression of testis and placental restricted genes in PAH lung. Heat map illustrating the neo-expression in human PAH lungs of testis and placenta restricted genes and their absence of expression in control lungs. (d, e) Highly specific and restricted genes expression in previously performed microarray. (d) Aberrant expression of the same highly specific germline, placental and embryonic stem cell genes and (e) the neo-expression in human PAH lungs of testis and placenta restricted genes from microarray expression data of experiments previously performed in human PAH. These microarray expression analyses were performed on 12 lungs from end-stage PAH vs. 11 control patients (GSE 53408) (black); two primary isolated smooth muscle cells of PAH patients vs. two primary isolated control smooth muscle cells (GSE 21284) (gray); lungs from eight PAH patients associated with pulmonary fibrosis vs. 13 controls (GSE 15197) (yellow); lung from 18 PAH patients vs. 13 controls (GSE 15197) (green).
Discussion

To our knowledge, this is the first study demonstrating the aberrant activation of normally silent tissue-specific genes in the lungs of human PAH patients. Indeed, 23 of the altered genes have already been demonstrated in PAH, but this is the first time that a systematic investigation of off-context gene expression has been done in the context of PAH. This demonstration of an ectopic gene expression in PAH gives the first strong evidence of a cancer-like identity crisis in PAH. This also reinforces the potential role of epigenetic modifications already suggested in PAH.\textsuperscript{12–16} This observation of an identity crisis in PAH strengthens the parallels that can be established between the PAH condition and cancer where a similar finding has been reported.

Conflict of interest

The author(s) declare that there is no conflict of interest.

Funding

This project in S. Khochbin’s team is supported by the Université Grenoble Alpes ANR-15-IDEX-02 program.

References

1. Voelkel NF, Cool C, Lee SD, et al. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114: 225S–230S.
2. Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 558–564.
3. Sutendra G and Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab 2014; 19: 558–573.
4. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518–523.
5. Piperi C, Vlastos F, Farmaki E, et al. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med 2008; 12: 1495–1501.
6. Girerd B, Perros F, Antigny F, et al. KCNN3: new gene target for pulmonary hypertension? Expert Rev Respir Med 2014; 8: 385–387.
7. Aldred MA, Comhair SA, Varella-Garcia M, et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 1153–1160.
8. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite instability of endothelial cell growth and apoptosis genes within pleomorphic lesions in primary pulmonary hypertension. Circ Res 2001; 88: e2–e11.
9. Eichstaedt CA, Song J, Viales RR, et al. First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension. Clin Sci Lond Engl 2017; 131: 689–698.
10. Gerlinger M and Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010; 103: 1139–1143.
11. Meloche J, Pflieger A, Vaillancourt M, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014; 129: 786–797.
12. Zhao L, Chen CN, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012; 126: 455–467.
13. Meloche J, Potus F, Vaillancourt M, et al. Bromodomain containing protein-4: the epigenetic origin of pulmonary arterial hypertension. Circ Res 2015; 117: 525–535.
14. Archer SL, Marsboom G, Kim GH, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010; 121: 2661–2671.
15. Hautefort A, Chesne J, Preussner J, et al. Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. *Oncotarget* 2017; 8: 52995–53016.

16. Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. *J Exp Med* 2011; 208: 535–548.

17. Rousseaux S, Debernardi A, Jacquiau B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. *Sci Transl Med* 2013; 5: 186ra66.

18. Greaves M and Maley C. Clonal evolution in cancer. *Nature* 2012; 481: 306–313.

19. Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. *J Clin Invest* 1998; 101: 927–934.

20. Kupershmidt I, Su QJ, Grewal A, et al. Ontology-based meta-analysis of global collections of high-throughput public data. *PLoS One* 2010; 5: e13066.

21. Anjum F, Lazar J, Zein J, et al. Characterization of altered patterns of endothelial progenitor cells in sickle cell disease related pulmonary arterial hypertension. *Pulm Circ* 2012; 2: 54–60.

22. Fratta E, Coral S, Covre A, et al. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. *Mol Oncol* 2011; 5: 164–182.